Join to View Full Profile
9500 Euclid AvenueTaussig Cancer institute, Cleveland ClinicCleveland, OH 44195
Phone+1 216-444-6833
Dr. Abraham is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Professor of Medicine at Lerner College of Medicine of Cleveland Clinic and Director of Breast Oncology Program at Taussig Cancer Institute, Cleveland Clinic. Member of Breast Cancer Working Committee and Breast Cancer Translational Commitee of NRG Oncology Research Group. Principal Investigator of NSABP studies at Cleveland Clinic. Co- PI of the NCI CTN - LAPS grant at case comprehensive cancer center.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1997 - 2001
University of ConnecticutResidency, Internal Medicine, 1994 - 1997
Calicut Medical CollegeClass of 1991
Certifications & Licensure
OH State Medical License 2013 - 2027
PA State Medical License 2024 - 2026
WV State Medical License 2000 - 2026
CT State Medical License 1996 - 2001
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014-2017
Clinical Trials
- BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy Start of enrollment: 2000 Sep 01
- Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer Start of enrollment: 2003 Jan 01
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer Start of enrollment: 2004 Jul 01
Publications & Presentations
PubMed
- 5 citationsTrastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.Sibylle Loibl, Yeon Hee Park, Zhiming Shao, Chiun-Sheng Huang, Carlos Barrios
The New England Journal of Medicine. 2026-02-26 - 1 citationsHuman Epidermal Growth Factor Receptor 2 Positivity a Moving Target in the Era of Antibody-Drug Conjugates.Marko Velimirovic, Jame Abraham
JCO Oncology Practice. 2026-01-01 - 12 citationsNCCN Guidelines® Insights: Breast Cancer, Version 5.2025.William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft
Journal of the National Comprehensive Cancer Network. 2025-11-01
Journal Articles
- Palliative Care Training during Fellowship: A National Survey of US Hematology and Oncology FellowsThomas RA, Curley B, Wen S, Zhang J, Abraham J, Moss AH,, J Palliat Med, 1/22/2015
- Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in wome...Abraham J, Robidoux A, Tan AR, Limentani S, Sturtz K, Shalaby I, Alcorn H, Buyse ME, Wolmark N, Jacobs SA, Breast Cancer Res Treat, 1/1/2015
- Radiation Exposure in Patients with Newly Diagnosed Breast Cancer within First Year from Diagnostic ProceduresChaudhary L., Knapp S., Hester S., Wen S., Xiao J., Marano G., Kurian S., Hazard H., Layne G., Jacobson G., Abraham J., Journal of Community and Supportive Oncology, 1/1/2015
Books/Book Chapters
Abstracts/Posters
- Graded Prognostic Assessment (GPA) for Her2 positive Breast Cancer with Brain Metastases (BCBM) in a Contemporary Cohort.Chi M, Venur VA, Mohammadi AM et al, American Society of Clinical Oncology (ASCO), 1/1/2015
- New graded prognostic assessment (GPA) in breast cancer brain metastases in a contemporary cohort.Ahluwalia M, Chi M, Venur VA, Budd T, et al, San Antonio Breast Cancer Symposium (SABCS), 1/1/2014
- Graded prognostic assessment for triple negative breast cancer brain metastases.Chi M, Venur VA, Abraham J, Budd T et al, San Antonio Breast Cancer Symposium (SABCS), 1/1/2014
Lectures
- NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Management of Metastatic Breast Cancer.1/10/2015
- Breast Cancer update 2014.1/5/2015
Other
- "Bethesda Handbook of Clinical Oncology, Fourth Edition, (ISBN: 0-787-2300-0) Lippincott-Williams and Wilkins, Philadelphia"Jame Abraham MD, Carmen Allegra MD, and James Gulley MD, PhD, National Cancer Institute, National Institutes of Health (Editors)
www.lww.com
1/1/2014 - Lessons from Pink.Abraham J., Community Oncology
1/1/2013 - Ipilimumab: New Treatment for melanoma.Abraham J., Community Oncology
1/1/2010
Authored Content
- Dr Jame Abraham of Cleveland Clinic on When Doctors Feel VulnerableNovember 2021
- All the News That's Fit to Tweet: ESMO 2020September 2020
- 3 Studies Presented at SABCS That Will Change Our PracticeDecember 2019
Press Mentions
Artificial Intelligence in Oncology (Podcast)November 26th, 2025- THE WEEK Health Summit 2025 | Can Breast Cancer Be Prevented with a Vaccine? Cleveland Clinic Reveals Stunning ProgressNovember 15th, 2025
- HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical SettingsOctober 27th, 2025
Professional Memberships
- Member
- Member
- Member
Other Languages
- Hindi, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
